Aktienanalyse zu bioAffinity Technologies Inc (BIAF)BIAFbioAffinity Technologies Inc

bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Currently, bioAffinity Technologies Inc (BIAF) is not a strong buy due to its significant financial challenges. The stock is trading at $2.78, which is 96.55% below its 52-week high of $80.70, indicating severe underperformance. Additionally, the company reported a staggering 84.81% year-to-date decline, and its recent revenue dropped by 27% to $1.4 million in Q1 2026. While there are some positive signs, such as a recent partnership with AvMEDICAL, the ongoing losses and negative cash flow are concerning. The main risk is the net income, which has been consistently negative, with a reported loss of $3.36 million in Q2 2026.